Eczema Research Study
Researchers at Stanford University are conducting a study to assess the safety, tolerability, and preliminary efficacy of soquelitinib treatment in participants with atopic dermatitis (also known as eczema).
Fast Facts
Ages 18+
Moderate to Severe Eczema
Failed Treatments for Eczema
Conducted in the Bay Area, CA
Study Background
Stanford University is conducting a trial of a medication to treat participants with moderate to severe eczema.
Researchers are conducting a 28-day study for patients with moderate to severe atopic dermatitis (AD) to assess the safety, tolerability, and preliminary efficacy of soquelitinib.
Participants have a 3 in 4 chance of being assigned to the active study drug and a 1 in 4 chance of being assigned to the placebo in one of four cohorts with varying doses. The study involves six visits overall including Screening, Days 1, 8, 15, and 28, and a 30-day Follow-up after the last dose.
Study Background
Stanford University is conducting a trial of a medication to treat participants with moderate to severe atopic dermatitisa.
Researchers are conducting a 28-day study for patients with moderate to severe atopic dermatitis (AD) to assess the safety, tolerability, and preliminary efficacy of soquelitinib.
Participants have a 3 in 4 chance of being assigned to the active study drug and a 1 in 4 chance of being assigned to the placebo in one of four cohorts with varying doses. The study involves six visits overall including Screening, Days 1, 8, 15, and 28, and a 30-day Follow-up after the last dose.
Additional Information
The purpose of this research study is to assess the safety, tolerability, and preliminary efficacy of soquelitinib treatment in participants with atopic dermatitis.
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18+
- Have moderate to severe eczema that a doctor has confirmed
- Have not had success with or couldn’t use other prescribed creams, medications, or treatments for eczema
Studies are conducted at the Stanford Redwood City campus and will include:
- Physical examinations
- Blood and urine sample collection
- Review of current and past medical history and medications
- 12-lead ECG
- Vital signs
- Skin assessments
- Patient questionnaires
- An ongoing review of any adverse events
- A chest x-ray may also be completed if TB testing is positive.
You will be compensated $90.00 per completed screening, days 8 and 15, and follow-up visits and $270.00 per completed days 1 and 28. The total compensation for completing all study visits and procedures is $990.00.
There is no cost for you to participate in our research study. Reasonable pre-approved travel costs may be reimbursed with supporting documentation.
